Details

Autor(en) / Beteiligte

• Leigh, D.
• Cram, D.S.
• Rechitsky, S.
• Handyside, A.
• Wells, D.
• Munne, S.
• Kahraman, S.
• Grifo, J.
• Katz-Jaffe, M.
• Rubio, C.
• Viotti, M.
• Forman, E.
• Xu, K.
• Gordon, T.
• Madjunkova, S.
• Qiao, J.
• Chen, Z.-J.
• Harton, G.
• Gianaroli, L.
• Simon, C.
• Scott, R.
• Simpson, J.L.
• Kuliev, A.

Titel

PGDIS position statement on the transfer of mosaic embryos 2021

Ist Teil von

• Reproductive biomedicine online, 2022-07, Vol.45 (1), p.19-25

Ort / Verlag

Netherlands: Elsevier Ltd

Erscheinungsjahr

2022

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Chromosome testing strategies, such as preimplantation genetic testing for aneuploidy (PGT-A), improve initial IVF outcomes by avoiding unwitting transfer of aneuploid embryos in morphology-based selection practices. Newer technologies have revealed that some embryos may appear to have intermediate whole chromosome (or parts of a chromosome termed segmental) copy number results suggesting trophectoderm mosaicism. An embryo with a trophectoderm mosaic-range result may be the only option for transfer for some patients. Recent data suggest that such mosaic embryos can be transferred without added risk of abnormal birth outcomes but may be associated with increased implantation failure and miscarriage rates, with higher values of mosaicism appearing to be less favourable for producing good outcomes. In this Position Statement, we provide guidance to laboratories, clinics, clinicians and counsellors to assist in discussions on the utility and transfer of mosaic embryos.